HYDROXOCOBALAMIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydroxocobalamin and what is the scope of patent protection?
Hydroxocobalamin
is the generic ingredient in four branded drugs marketed by Merck, Btg Intl, Abraxis Pharm, Actavis, Watson Labs, and Bel Mar, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for hydroxocobalamin. Three suppliers are listed for this compound.
Summary for HYDROXOCOBALAMIN
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Master File Entries: | 4 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 11 |
| Patent Applications: | 870 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in HYDROXOCOBALAMIN? | HYDROXOCOBALAMIN excipients list |
| DailyMed Link: | HYDROXOCOBALAMIN at DailyMed |
Recent Clinical Trials for HYDROXOCOBALAMIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 4 |
| General Oncology, Inc. | Phase 1 |
| Joshua Korzenik | Phase 2 |
Pharmacology for HYDROXOCOBALAMIN
| Drug Class | Antidote |
Medical Subject Heading (MeSH) Categories for HYDROXOCOBALAMIN
US Patents and Regulatory Information for HYDROXOCOBALAMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 085998-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck | ALPHAREDISOL | hydroxocobalamin | INJECTABLE;INJECTION | 080778-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Btg Intl | CYANOKIT | hydroxocobalamin | INJECTABLE;INJECTION | 022041-001 | Apr 8, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abraxis Pharm | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 084921-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bel Mar | HYDROXOMIN | hydroxocobalamin | INJECTABLE;INJECTION | 084629-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Watson Labs | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 085528-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Btg Intl | CYANOKIT | hydroxocobalamin | INJECTABLE;INJECTION | 022041-002 | Dec 15, 2006 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HYDROXOCOBALAMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Btg Intl | CYANOKIT | hydroxocobalamin | INJECTABLE;INJECTION | 022041-002 | Dec 15, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
| Btg Intl | CYANOKIT | hydroxocobalamin | INJECTABLE;INJECTION | 022041-001 | Apr 8, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for HYDROXOCOBALAMIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| SERB SA | Cyanokit | hydroxocobalamin | EMEA/H/C/000806 Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures. |
Authorised | no | no | no | 2007-11-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
